You are here: Industry Insights > Amgen

News List

Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018 pharmafile
December 07, 2018
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational novel bispecific T cell engager (BiTE) immunotherapies...
Amgen, UCB Announce FDA to Review Evenity americanpharmaceuticalreview
December 04, 2018
Amgen and UCB announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data ......
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture firstwordpharma
December 02, 2018
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVE
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz pharmafile
November 28, 2018
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s Neulasta, the company has announced.
Amgen Receives CHMP Positive Opinion to Expand Use of Blincyto americanpharmaceuticalreview
November 20, 2018
Amgen announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ado
Provention Bio to develop Amgen’s celiac disease candidate pharmaceutical-technology
November 10, 2018
Biopharmaceutical company Provention Bio has agreed to further develop Amgen’s AMG 714 drug candidate for the treatment of gluten-free diet non-responsive celiac disease (NRCD).
Provention Bio to develop Amgen’s celiac disease candidate pharmaceutical-technology
November 10, 2018
Biopharmaceutical company Provention Bio has agreed to further develop Amgen’s AMG 714 drug candidate for the treatment of gluten-free diet non-responsive celiac disease (NRCD).
Amgen cuts price of cholesterol drug Repatha by 60% pharmaceutical-technology
October 29, 2018
Amgen has announced plans to reduce the price of its cholesterol drug Repatha by 60% to $5,850 per year, in an effort to improve affordability through lowering patient copays.
Orion and Amgen to collaborate on the commercialisation of AMGEVITA (biosimilar adalimumab) in Finland October 25, 2018
Orion and Amgen to collaborate on the commercialisation of AMGEVITA (biosimilar adalimumab) in Finland
Amgen launches first biosimilar of best-selling Humira in Europe pharmatimes
October 19, 2018
Amgen has announced the launch of a proprietary biosimilar version of Abbvie's best-selling drug Humira (adalimumab) across all European markets, beginning 16 October.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page